Pay in 4 interest-free payments of $6.99 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
More recently, the SUMMIT trial demonstrated that tirzepatide reduced the composite risk of cardiovascular death or worsening heart failure by 38% (HR = 0.62, 95% CI: 0.410.95) in patients with heart failure with preserved ejection fraction (HFpEF) and a BMI 30 kg/m 2 , 32% of whom also had type 2 diabetes
Greater waist circumference reduction at week 20 was associated with lower subsequent MACE risk, suggesting that reduction in central adiposity (visceral fat around the organs) may contribute to cardiovascular protection
Choose retatrutide if the research question specifically targets hepatic steatosis, fat oxidation, or the glucagon-axis contribution to energy expenditure, and if you can tolerate a thinner Phase 3 evidence base and longer titration window
This novel mechanism enhances insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite, making it effective for glycemic control and weight reduction
US$ 24.82
US$ 20.30
US$ 29.00
US$ 28.61
US$ 20.72
US$ 29.21
US$ 19.99
